Grant, Michael J.
Herbst, Roy S.
Goldberg, Sarah B.
Article History
Accepted: 4 May 2021
First Online: 24 June 2021
Competing interests
: S.B.G. has acted as a consultant of AstraZeneca, Boehringer Ingelheim, Bristol–Myers Squibb, Blueprint Medicine, Daiichi–Sankyo, Genentech, Janssen, Regeneron, Sanofi-Genzyme and Takeda, and has received research funding from AstraZeneca and Boehringer Ingelheim. R.S.H. has acted as a consultant of Abbvie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Bayer HealthCare Pharmaceuticals, Biodesix, Bolt Biotherapeutics, Bristol–Myers Squibb, Cybrexa Therapeutics, DynamiCure Biotechnology, eFFECTOR Therapeutics Inc., Eli Lilly and Company, EMD Serono, Foundation Medicine, Genentech/Roche, Genmab, Gilead, Halozyme Therapeutics, Heat Biologics, I-Mab Biopharma, Immunocore, Infinity Pharmaceuticals, Johnson and Johnson, Loxo Oncology, Merck and Company, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Oncternal Therapeutics, Pfizer, Refactor Health, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, STCube Pharmaceuticals Inc., Symphogen, Takeda, Tesaro, Tocagen, Ventana Medical Systems and WindMIL Therapeutics, has served on the advisory boards of AstraZeneca, Bolt Biotherapeutics, Candel Therapeutics, Checkpoint Therapeutics, Cybrexa Therapeutics, EMD Serono, I-Mab Biopharma, Immunocore, Infinity Pharmaceuticals, Neon Therapeutics, Novartis, Ocean Biomedical, Ribbon Therapeutics, STCube Pharmaceuticals Inc, and Xencor, and has received research funding from AstraZeneca, Eli Lilly and Company, Genentech/Roche, and Merck and Company, is a Board Member (non-executive/independent) for Immunocore Holdings Limited and Junshi Pharmaceuticals, and is a member of the Board of Directors for the International Association for the Study of Lung Cancer and the American Association for Cancer Research. M.J.G. declares no competing interests.